Bayer Says Cipla Generic Negates Critics Of Anti-Compulsory License Suit
This article was originally published in PharmAsia News
U.S.-based Bayer said the argument on its court fight in India to overturn a compulsory-licensing decision allowing Natco Pharma to market a generic of its Nexavar (sorafenib) cancer drug has been obviated by Cipla's launch of another generic.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
President Trump on 27 March signed into law a $2.2tn COVID-19 stimulus package that provides $80m to the US Food and Drug Administration for emergency use authorization of medical products. See what FDA commissioner Stephen Hahn said about it here.
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.